Stephen Philip Jackson
_Jackson_-_26837860422.jpg)
Stephen Philip Jackson (born July 17, 1962 in Nottingham ) is a British biochemist, pharmaceutical researcher and molecular biologist.
Jackson studied biochemistry at the University of Leeds with a bachelor's degree in 1983. He then went on to graduate studies with Jean Beggs at Imperial College London and the University of Edinburgh and received his PhD in 1987. The dissertation was about RNA splicing in yeast ( cloning and characterization of the RNA8 gene of Saccharomyces cerevisiae ). He was a post-doctoral student with Robert Tjian at the University of California, Berkeley . From 1991 he was a junior group leader at the Wellcome CRC Institute (now the Gurdon Institute ) at Cambridge University. He is now Senior Group Leader and Director of Cancer Research UK Laboratories there. He is also a Fellow of St. John's College in Cambridge and Frederick James Quick Professor of Biology in Cambridge and a member of the Wellcome Trust Sanger Institute .
He is known for research on the regulation of DNA repair, which has application in cancer research and cancer drug discovery. Jackson developed high-throughput screening methods that made promising candidates for cancer drugs (such as ovarian and breast cancer) at his company. In 1997 he founded KuDOS Pharmaceuticals (sold to AstraZeneca for $ 210 million in 2005 ) and Mission Pharmaceuticals in 2011.
In 2008 he received the GlaxoSmithKline Award, in 2011 the Buchanan Medal and in 2016 both the König Faisal Prize and the AH Heineken Prize for Medicine , and in 2019 the Léopold Griffuel Prize . He is a Fellow of the Royal Society (2008) and a Fellow of the Academy of Medical Sciences . In 1997 he became an EMBO member.
Web links
| personal data | |
|---|---|
| SURNAME | Jackson, Stephen Philip |
| BRIEF DESCRIPTION | British molecular biologist and biochemist |
| DATE OF BIRTH | 17th July 1962 |
| PLACE OF BIRTH | Nottingham |